Nycomed Gmbh

Takeda Gmbh

Astrazeneca Ab

Andrea Wohlsen

Degenhard Marx

Armin Hatzelmann

Hans-Peter Kley

Christof Zitt

Beate Schmidt

Geert Jan Sterk

Rolf-Peter Hummel

Christian Scheufler

Martin Feth

Wiro M P B Menge

Anke Heuser

Deborah Ockert

Johannes A M Christiaans

Dieter Flockerzi

Ulrich Kautz

Anna Rosiak

Jens Christoffers

Juergen Volz

Clemens Braun

Jürgen Volz

Stefan-Lutz Wollin

Johannes Barsig

Maria Vittoria Chiesa

The invention relates to the combined use of a PDE4 inhibitor with a HMG-CoA reductase inhibitor for the prevention and curative treatment of an inflammatory pulmonary disease.

Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases

The compound 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione is a novel effective inhibitor of the type 4 phosphodiesterase useful in the treatment of psoriasis or atopic dermatitis.

Pyrazolone derivatives as PDE4 inhibitors

The compound 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione is a novel effective inhibitor of the type 4 phosphodiesterase.

The compounds of a certain formula 1, in which R1, R7, R8, R9 and n have the meanings as given in the description, are novel effective inhibitors of the type 4 phosphodiesterase.

The compounds of formula I in which R1, R2 and R3 have the meanings as given in the description, are novel effective PDE4 inhibitors.

3-oxa-10-aza-phenanthrenes

The compounds of formula I in which A, R1, R2 and R3 have the meanings as given in the description, are novel effective PDE4 inhibitors.

3-thia-10-aza-phenanthrene derivatives

Growing community of inventors

Neuchatel, Switzerland

Andrea Wohlsen